Blood disorders affect millions of Americans, yet many don’t realize these conditions can sometimes transform into something far more serious. With approximately 1.3 million people currently living ...

The National Institute for Health and Care Excellence (NICE) has recommended exagamglogene autotemcel (Casgevy, Vertex) – commonly known as 'exa-cel' – to treat transfusion-dependent beta thalassaemia ...

A Roche drug in development for treating a rare blood disorder has Phase 3 data showing it worked at least as well as a blockbuster AstraZeneca drug while also offering patients a dosing advantage.

A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the burden of lifelong transfusions. A single one-time gene therapy could free ...

This month the FDA has approved a treatment for an inherited blood disorder. The Casgevy treatment was developed through CRISPR gene-editing technology and involves modifying a person’s own blood stem ...